立足产学研资源禀赋优势，建设科技创新活力区、产教融合未来新城，打造首都发展新增长极。6月25日，由北京海外高层次人才协会主办、昌平区委人 才工作领导小组办公室承办的HICOOL 2025全球创业大赛昌平赛区启动仪式在中关村生命科学园举行。北京市人才工作局副局长杨璞，北京海外学人中 心党委委员、副主任司鹏搏，北京海外学人中心人才服务三部部长袁少暐，未来科学城党工委委员、管委会副主任，昌平区政府党组成员、副区长（兼） 赵仕伟，昌平区委组织部副部长、区人才工作局局长宋松，北京海外高层次人才协会理事长关鸿亮，副理事长、秘书长武沂，以及昌平区委人才工作领导 小组相关成员单位、投资机构、孵化机构、创新企业代表、优秀人才代表等出席启动仪式。 作为首都重点发展的平原新城、北京国际科创中心的重要承载区，昌平区不仅是科教资源富集地，更是未来产业发展的策源高地。依托"医药健康+先进 能源+先进制造"三大千亿级产业集群，以及科技服务、科创金融、文旅农商体融合产业，昌平区形成了"3+2+1"现代产业体系，并汇聚41所全国重点高 校、40个国家级实验室和210个工程技术中心，构建了从基础研究到产业化的全链条创新生态，为全球创业者提供了全 ...

转自：北京日报客户端 立足产学研资源禀赋优势，打造首都发展新增长极——6月25日，HICOOL 2025全球创业大赛昌平赛区 启动。未来三天，来自全球的250余个生物技术/健康服务赛道优质项目将展开激烈角逐，项目覆盖基因 治疗、细胞工程、疫苗研发、血液制品、蛋白质合成、微生物技术、健康管理、数字医疗、康养服务及 医美科技等前沿领域。 此外，为加速项目落地，昌平区特设"人才会客厅"，由昌平区人才工作局、区投促中心、区科委、区经 信局、未来科学城管委会（生命园管委会）、中关村科技园区昌平园管委会、未来城集团、昌发展集 团、生命园公司等十余产业部门联合投资机构、孵化机构组建"赛事服务专班"，为参赛项目提供"一对 一"咨询对接服务，对接昌平区资金扶持、人才引进、产业支持及空间保障等政策。赛事期间，昌平区 还将组织参赛项目团队参观考察中关村生命科学园及重点科研平台，深入了解昌平区产业生态，加速科 技成果转化落地。 昌平区政府党组成员、副区长（兼）赵仕伟介绍，昌平区近年来大力发展医药健康产业，布局构建生命 科学创新走廊，先后出台"产业倍增行动计划"等一系列政策，加快打造具有全球竞争力的生命科学新高 地。目前，"生命谷"聚 ...

Group 1 - The core viewpoint emphasizes that the rise of new consumption is a result of specific economic cycles and social changes, with optional consumption surpassing essential consumption in the US and Japan during key periods of economic transformation [1][2][3] - Historical experiences from the US stock market show that optional consumption sectors have significantly outperformed essential consumption sectors, particularly during the 1970s and post-2009, driven by factors such as rising disposable income and shifts in consumer behavior [1][2] - The financial characteristics of new consumption reveal that sectors within optional consumption have seen increasing debt ratios while effectively managing risks, leading to improved fundamentals and higher valuation premiums [2][3] Group 2 - The driving factors behind the shift from essential to optional consumption include continuous growth in disposable income, technological advancements, and changes in demographic structures and consumer attitudes, particularly among younger generations [3][4] - The market structure is evolving, with leading companies in optional consumption leveraging scale effects and brand advantages to consolidate their market positions, as evidenced by successful companies in Japan's toy, beauty, and gaming sectors [3][4] - The report suggests that the experiences from the US and Japan can inform current investment strategies in the A-share market, focusing on sectors that meet diverse consumer needs and exhibit high growth potential [4][10]

Group 1 - The establishment of the Shandong branch of Zhongke Boai (Beijing) Health Technology Co., Ltd. in Jinan marks an important step in the company's national strategic layout and a commitment to the health sector in Qilu [2] - The company aims to provide high-quality and convenient health services by leveraging Shandong's cultural heritage and regional advantages, contributing to the "Healthy China" strategy [2] - The chairman, Cui Xiansheng, emphasizes the importance of mental health and plans to use professional knowledge to make significant contributions to society [2] Group 2 - The company has appointed experts from the Jinan Mental Health Association and Shandong Mental Health Center as advisory consultants, enhancing its professional capabilities [3] - Future plans include developing personalized health solutions based on local needs, increasing research investment, and integrating AI and big data with health services [3] - The company aims to build a health ecosystem in collaboration with local institutions, benefiting a wider community and supporting mental health initiatives in Qilu [3]

在银屑病的治疗上，外用药物适用于绝大多数患者，并且是首选治疗方式。卡泊三醇倍他米松软膏是银 屑病治疗的关键药物之一，得到《中国银屑病诊疗指南(2023版)》一线推荐和《2020美国皮肤病学会 (AAD)指南》A级推荐。在此之前，卡泊三醇倍他米松软膏只有一款原研产品，患者选择十分有限。此 次重庆华邦旗下卡泊三醇倍他米松乳膏上市，将为国内银屑病患者提供更多用药选择。 华邦®卡泊三醇倍他米松软膏采用了卡泊三醇与二丙酸倍他米松的复方配方，充分发挥了两种成分的协 同作用。卡泊三醇能够抑制角质形成细胞的异常增殖，促进其正常分化，同时具有抗炎和免疫调节作 用；而二丙酸倍他米松则以强效抗炎和免疫抑制功能，帮助缓解银屑病症状。 值得一提的是，华邦制药的卡泊三醇倍他米松软膏起效成分纯度更高，产品质量更稳定，且价格更为优 惠，为患者提供了更经济有效的治疗选择。 此次华邦制药的卡泊三醇倍他米松乳膏在京东健康全网首发标志着华邦制药与京东健康合作重要升级。 京东健康作为行业领先的医疗健康服务企业，拥有庞大的用户基础，并构建了完善的医疗健康服务体 系，包括在线问诊、药品配送、健康管理等一站式服务。这些优势将进一步提升华邦卡泊三醇倍他米松 ...

当收入对公众幸福感的影响力五年骤降25%，当"健康"取代"收入"成为国民幸福的首要指标，一场关于 美好生活的价值重构正在发生。 2019年，65.74%的中国人将收入水平视为幸福的首要来源；五年后的2024年，这个数字下跌至 40.64%。取而代之的，是健康状况以53.44%的占比，跃居国民幸福感影响因素首位。 上述颠覆性结论源自6月15日发布的"2024-2025年度美好生活大调查"。这项由中央广播电视总台、国家 统计局、中国邮政集团有限公司以及北京大学国家发展研究院联合开展的全球最大规模民生感受型调 查，覆盖全国10万家庭，清晰勾勒出中国社会从"求富"向"求福"的集体转向。 同期举办的《数说美好》圆桌对话及《美好生活城市之夜》晚会中，数据洞察之上，"何为美好""何以 美好"的图景清晰呈现：国民对美好生活的追求，正经历从物质富足向精神丰盈的结构性变迁——健康 状况、家庭关系、收入水平、婚姻情感、兴趣爱好构成核心"幸福砝码"。兴趣社群在提升公众生活质 量、拓展社交圈层、改善身心健康等维度发挥重要作用，成为社会自组织新样态，构建城市人民美好生 活的新场景。 何为美好 美好生活要素展现全新维度 2024至2025 ...

凭借在大病救助、保险科技及健康服务行业的贡献，沈鹏获得了社会的广泛认可，曾获评"北京市就业创业工作先进个人"、 "北京榜样·支援合作先锋"、 "民 建参与脱贫攻坚先进个人" 、"首都民族团结进步先进个人"等荣誉称号，入选《福布斯》"30位30岁以下亚洲精英榜"、《财富》"中国40位40岁以下商界精英 榜"、 世界经济论坛"全球青年领袖"、粤港澳大湾区杰出青年企业家等，并担任中华全国工商联青年企业家委员会委员、全国青联第十三届委员会委员、北 京市工商业联合会执委常委等社会职务。 面对新一轮的科技浪潮，沈鹏表示："抓住AI产业化的时代机遇，利用科技优势，优化产品与服务，满足用户多元化的需求。"水滴公司积极推进"All in AI"战略，从内到外全面拥抱AI，鼓励员工积极探索AI应用场景，共同挖掘其在业务提效上的巨大潜力，拓展全球化布局，让科技真正惠及亿万家庭。（一 言） 此次创新争先活动由北京市科协主办，旨在团结引导广大科技工作者凝心聚力、奋勇争先，更好地服务北京国际科技创新中心和高水平人才高地建设。作为 保险科技与医疗健康领域的创新者和引领者，沈鹏带领水滴公司坚持技术创新赋能行业发展，持续推动人工智能、大数据等 ...

DocGo (DCGO) FY 2025 Annual General Meeting June 17, 2025 12:00 PM ET Speaker0 Welcome to DOTGO's twenty twenty five annual meeting of stockholders. My name is doctor Steven Clasco, chair of the board of DOTGO, and I will serve as chair of today's meeting. The time is shortly after 12PM, and I now call the meeting to order. I note that the polls are open. You may vote your shares online at any time during this meeting before the polls close. If you previously voted via the Internet, telephone, or the return ...

Summary of LifeStance Health Group (LFST) FY Conference Call - June 10, 2025 Company Overview - LifeStance Health Group is a leader in outpatient mental health services with approximately 7,500 clinicians and over 8 million visits annually across 550 locations in 33 states [4][5][6]. Core Strategies and Management Transition - The management transition from Ken Burdick to Dave Borden as CEO and Ryan McGordy as CFO is expected to be seamless, with a continued focus on clinical and operational excellence [3][9]. - The company aims to maintain a strategy centered on profitable growth, disciplined capital deployment, and enhancing patient and clinician experiences [7][12]. Operational Milestones - Key operational milestones include the rollout of a consistent operating model, a digital patient check-in tool, and improvements in cash collections leading to a positive free cash flow of over $85 million [13][14]. - The company achieved double-digit adjusted EBITDA margins and positive net income for the first time in Q1 2025 [14]. Growth and Hiring Strategy - The clinician base grew by 17% in 2023, with a focus on filling existing clinician schedules rather than solely organic hiring [20][22]. - The company plans to maintain low double-digit clinician growth to support mid-teens revenue growth targets [27][29]. Retention and Competitive Landscape - Despite stable turnover rates, the company is implementing initiatives to improve clinician retention, including changes to payroll frequency and the introduction of cash-based productivity bonuses [34][36]. - LifeStance continues to attract new clinicians, particularly those seeking W-2 benefits and flexible working conditions [40][42]. Financial Performance and Projections - The company anticipates low to mid-single-digit rate increases from payers, with expectations for continued growth in revenue per visit [46][50]. - LifeStance aims for mid-thirties gross margins and 15-20% EBITDA margins in the long term, driven by operational efficiencies and leveraging G&A costs [78][80]. Investment in Technology and Infrastructure - The company is in the early stages of evaluating EHR solutions to enhance clinician and patient experiences, with a decision expected by the end of 2025 [75][76]. - Investments in technology and operational efficiencies are seen as critical for future growth and margin expansion [72][69]. Conclusion - LifeStance Health Group is positioned for continued growth in the outpatient mental health sector, with a strong focus on operational excellence, clinician retention, and strategic investments in technology and infrastructure to support long-term profitability [44][80].

Core Viewpoint - The deep integration of modern service industry and advanced manufacturing (referred to as "two-industry integration") is crucial for cultivating a modern industrial system and achieving high-quality development, as well as for developing new types of productivity [1] Group 1: Pilot Demonstration Units - Beijing has recently recognized the second batch of city-level pilot demonstration units for two-industry integration, including three demonstration parks and 32 pilot enterprises [1] - The three newly selected demonstration parks are: 1. Chaoyang New Quality Productivity Integration Demonstration Pilot Area, with a management area of 26.9 square kilometers and an annual revenue share of 62% from two-industry integration enterprises [2] 2. Tongzhou City Sub-center Future Design + Health Integration Innovation Demonstration Area, with a management area of 25.5 square kilometers and an annual revenue share of over 50% from two-industry integration enterprises [3] 3. Western Beijing Yongding River Two-Industry Integration Demonstration Park, with a management area of 26.43 square kilometers and an annual revenue share of over 66% from two-industry integration enterprises [3] Group 2: Focus Areas and Development Paths - The Chaoyang Park focuses on the integration of new generation information technology and service industry, as well as high-end equipment and service integration, exploring paths such as "new generation information technology + technology services + intelligent manufacturing" [2] - The Tongzhou Park emphasizes the integration of pharmaceutical manufacturing and health services, and research design and manufacturing, exploring paths like "pharmaceutical research design + manufacturing + health services" [3] - The Western Beijing Park focuses on the integration of new generation information technology with manufacturing and service industries, and pharmaceutical manufacturing with health services, exploring paths such as "artificial intelligence + application scenarios" [3] Group 3: Pilot Enterprises - The second batch includes 32 city-level two-industry integration pilot enterprises, comprising 10 leading pilot enterprises and 22 growth-type pilot enterprises, covering seven key areas of integration development across 11 districts and the Beijing Economic and Technological Development Zone [4] - Notable enterprises include Qihoo 360 Technology Co., Ltd., with pilot enterprises in fields such as new generation information technology and manufacturing service integration, pharmaceutical manufacturing and health services, and high-end equipment and service integration [4] Group 4: Future Development Plans - The Beijing Municipal Development and Reform Commission plans to continue nurturing and constructing two-industry integration pilot demonstrations, aiming to create a "ten parks and hundred enterprises" development pattern [4] - The focus will be on summarizing the development models, typical cases, and benchmark enterprises of Beijing's two-industry integration, forming replicable models to guide market entities in achieving empowerment, efficiency enhancement, and transformation [4]